- Home
- TCRX vs STHO Comparison
TCRX vs STHO Comparison
Compare TCRX & STHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- STHO
- Stock Information
- Founded
- TCRX 2018
- STHO N/A
- Country
- TCRX United States
- STHO United States
- Employees
- TCRX N/A
- STHO N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- STHO Real Estate
- Sector
- TCRX Health Care
- STHO Real Estate
- Exchange
- TCRX Nasdaq
- STHO Nasdaq
- Market Cap
- TCRX 90.5M
- STHO 89.7M
- IPO Year
- TCRX 2021
- STHO N/A
- Fundamental
- Price
- TCRX $1.27
- STHO $6.53
- Analyst Decision
- TCRX Strong Buy
- STHO
- Analyst Count
- TCRX 7
- STHO 0
- Target Price
- TCRX $9.86
- STHO N/A
- AVG Volume (30 Days)
- TCRX 389.5K
- STHO 93.2K
- Earning Date
- TCRX 05-06-2025
- STHO 05-20-2025
- Dividend Yield
- TCRX N/A
- STHO N/A
- EPS Growth
- TCRX N/A
- STHO N/A
- EPS
- TCRX N/A
- STHO N/A
- Revenue
- TCRX $4,421,000.00
- STHO $113,297,000.00
- Revenue This Year
- TCRX $47.30
- STHO N/A
- Revenue Next Year
- TCRX $74.30
- STHO N/A
- P/E Ratio
- TCRX N/A
- STHO N/A
- Revenue Growth
- TCRX N/A
- STHO N/A
- 52 Week Low
- TCRX $1.02
- STHO $6.09
- 52 Week High
- TCRX $9.69
- STHO $14.50
- Technical
- Relative Strength Index (RSI)
- TCRX 37.62
- STHO 42.45
- Support Level
- TCRX $1.32
- STHO $6.11
- Resistance Level
- TCRX $1.65
- STHO $7.02
- Average True Range (ATR)
- TCRX 0.12
- STHO 0.35
- MACD
- TCRX -0.02
- STHO 0.06
- Stochastic Oscillator
- TCRX 0.00
- STHO 46.41
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties and land and development properties.